Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Spinal Cord Neoplasms 1Rhabdoid Tumor 1Pheochromocytoma 1Paraganglioma, Extra-Adrenal 1Paraganglioma 1Optic Nerve Glioma 1Oligodendroglioma 1Neuroblastoma 1Medulloblastoma 1Familial ependymoma 1Choroid Plexus Neoplasms 1Carcinoma, Medullary 1Astrocytoma 1Adenocarcinoma, Follicular 1

Interventions

vandetanib 5selpercatinib 4Everolimus 4cabozantinib 3Sorafenib 3lenvatinib 2Trastuzumab 2Temozolomide 2Sunitinib 2Octreotide 2Gefitinib 2Capecitabine 2veliparib 1vatalanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1temsirolimus 1tanespimycin 1sargramostim 1sacubitril and valsartan sodium hydrate drug combination 1pralsetinib 1pentetreotide 1pazopanib 1motesanib diphosphate 1mercaptoundecahydrododecaborate 1lutetium Lu 177 dotatate 1cixutumumab 1aldesleukin 1Vorinostat 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Medullary × Vorinostat × Endocrine × Clear all
NCT00134043 2014-08-11

Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Completed
19 enrolled 11 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡